

FISCAL IMPACT OF PROPOSED LEGISLATION**Measure: HB 3380 - A**

82nd Oregon Legislative Assembly – 2023 Regular Session

Legislative Fiscal Office

Only Impacts on Original or Engrossed Versions are Considered Official

Prepared by: MaryMichelle Sosne

Reviewed by: Haylee Morse-Miller, Ben Ruef, Steve Robbins

Date: 4/5/2023

Measure Description:

Allows physician to prescribe continuous glucose monitor to certain patients whether or not physician specializes in endocrinology.

Government Unit(s) Affected:

Department of Consumer and Business Services, Oregon Medical Board, Board of Pharmacy, Oregon Health Authority

Summary of Fiscal Impact:

Costs related to the measure may require budgetary action - See analysis.

Analysis:

HB 3380-1 replaces the introduced version of the measure. The measure requires the Oregon Health Plan to provide coverage for prescribed continuous glucose monitors in certain circumstances. The measure applies to prescriptions issued on or after January 1, 2024.

Currently, the Oregon Health Authority (OHA) provides coverage for continuous glucose monitors to individuals with Type 1 diabetes and the coverage has a 45% utilization rate. Assuming the same level of utilization and based solely on the cost of monitoring taken from coordinated care organization and fee-for-service pharmacy claims, 4,555 individuals with Type 2 diabetes could receive coverage for continuous glucose monitors. The biennial fiscal impact of adding coverage for this population is \$7,231,404 General Fund and \$16,402,112 Federal Funds. The fiscal impact is subject to change based on overall utilization.

The measure has a minimal fiscal impact to the Department of Consumer and Business Services, the Oregon Board of Pharmacy, and the Oregon Medical Board.

This measure warrants a subsequent referral to the Joint Committee on Ways and Means for consideration of its budgetary impact on the State's General Fund.